Pharmaceutical Executive-11-01-2014

Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.

Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.

By rethinking the role of the sales rep and the new skills it demands, pharma companies can put themselves in a prime competitive position.

The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.

Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.